Monthly Prescribing Reference

FDA Approves Juvéderm Voluma XC to Improve Temple Hollowing

At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
Pharm Exec

FDA Approves AbbVie’s Juvederm Voluma XC for the Treatment of Moderate to Severe Temple Hollowing

This marks the first time that a hyaluronic acid dermal filler has received FDA approval for temple hollowing. Allergan Aesthetics, an AbbVie company, announced that the FDA has approved Juvéderm ...
Stockhouse

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the ...
Stockhouse

Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing

"The number one facial concern patients have is the eye area,12 so it is essential to consider treating the temples as part of a comprehensive treatment plan. With the approval and training-led launch ...
Nasdaq

AbbVie's Allergan Aesthetics Gets FDA Nod For Juvederm Voluma XC For Temple Hollows

(RTTNews) - Drug manufacturer AbbVie Inc. (ABBV), Tuesday announced that its subsidiary Allergan Aesthetics received approval from the U.S. Food and Drug Administration or FDA regarding Juvederm ...
Miami Herald

Juvéderm Voluma XC combats aging by lifting, sculpting and adding volume to the cheeks

Dermatologists and plastic surgeons have a new, nonsurgical weapon to add to their anti-aging arsenal. Juvéderm Voluma XC was approved by the U.S. Food and Drug Administration in December as the first ...